The addition of cetuximab to preoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma is associated with high rate of long term survival: Mature results from a prospective phase Ib/II trial.
Cetuximab
Chemoradiotherapy
Esophageal Cancer
Neoadjuvant treatment
Squamous cell carcinoma
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
30
08
2018
revised:
07
01
2019
accepted:
10
01
2019
entrez:
22
4
2019
pubmed:
22
4
2019
medline:
14
3
2020
Statut:
ppublish
Résumé
This phase IB/II study evaluated the safety and efficacy of the addition of cetuximab to standard preoperative chemoradiotherapy (CRT) in locally advanced esophageal cancer (LAEC). Patients (pts) with resectable LAEC (T 64 pts were treated and 60 completed CRT. Median age was 65 years and 66% were males. Adenocarcinoma/squamous ratio was 61%/39%. Tumors were advanced: 95% T This study suggests that the addition of cetuximab to standard preoperative CRT is feasible. R0, pCR and local control rates are encouraging. Pts with squamous cell tumors benefited more from the addition of cetuximab.
Identifiants
pubmed: 31005227
pii: S0167-8140(19)30018-0
doi: 10.1016/j.radonc.2019.01.013
pii:
doi:
Substances chimiques
Cetuximab
PQX0D8J21J
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
74-80Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.